Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

0.2948 -0.0952 (-24.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,973,171
Open 0.3900
Bid (Size) 0.3000 (153)
Ask (Size) 0.3009 (360)
Prev. Close 0.3900
Today's Range 0.2700 - 0.3931
52wk Range 0.2700 - 1.020
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Legal Battle Brews Over 23andMe's Customer Data Breach Settlement And Arbitration Claimants
Lawyer raises objections to 23andMe's proposed $30 million settlement, arguing it undermines arbitration rights for 5,000 customers following a data breach. The court is set to review the case in late... 
Via Benzinga
Topics Data Breach
Exposures Information Security
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga

Performance

YTD
-67.55%
-67.55%
1 Month
-5.24%
-5.24%
3 Month
-30.83%
-30.83%
6 Month
-37.95%
-37.95%
1 Year
-65.66%
-65.66%

More News

Read More
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
From 23andMe, Inc.
Via GlobeNewswire
Independent Board Members Of Penny Stock 23andMe Resign, Call Out CEO Anne Wojcicki For Not 'Actionable Proposal' Despite Ample Time
Via Benzinga
Looking Into 23andMe Holding's Recent Short Interest
Via Benzinga
General Mills, Steelcase And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Independent Directors of 23andMe Resign from Board
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
From 23andMe, Inc.
Via GlobeNewswire
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
From 23andMe, Inc.
Via GlobeNewswire
Why Affirm Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
From 23andMe, Inc.
Via GlobeNewswire
ME Stock Earnings: 23andMe Holding Beats EPS, Misses Revenue for Q1 2025
Via InvestorPlace
23andMe Reports First Quarter Fiscal 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
ME Stock Alert: CEO Anne Wojcicki Enters $200 Million Buyout Offer for 23andMe
Via InvestorPlace
23andMe Special Committee responds to CEO’s take-private proposal
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces CEO’s Take-Private Proposal
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q1 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
From 23andMe, Inc.
Via GlobeNewswire
The 3 Best Personalized Nutrition Stocks to Buy Now
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME
From Kahn Swick & Foti, LLC
Via Business Wire
3 High-Dividend Stocks to Buy if You Are Seeking Consistent Payouts
Via InvestorPlace
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
From 23andMe, Inc.
Via GlobeNewswire
3 Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right This Instant
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.